Tags

Type your tag names separated by a space and hit enter

Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer.

Abstract

The efficacy and safety of consuming high-dose isoflavone supplements for prostate cancer is not clear. A double-blind, placebo controlled, randomized trial was conducted in 53 men with prostate cancer enrolled in an active surveillance program. The treatment group consumed a supplement containing 450 mg genistein, 300 mg daidzein, and other isoflavones daily for 6 mo. Prostate-specific antigen (PSA) was measured in both groups at baseline, 3 mo, and 6 mo, and serum concentrations of genistein, daidzein, and equol were assessed at baseline and 6 mo in the treatment group. Following the completion of the 6-mo double-blind study, men were enrolled in a 6-mo open label trial with the same isoflavone-rich supplement, and PSA was measured at 3 and 6 mo. PSA concentrations did not change in either group after 6 mo or after 12 mo when the open-label study was included. The 6 mo serum concentrations of genistein and daidzein (39.85 and 45.59 μmol/l, respectively) were significantly greater than baseline values and substantially higher than levels previously reported in other studies. Equol levels did not change. Although high amounts of aglycone isoflavones may result in significantly elevated serum concentrations of genistein and daidzein, these dietary supplements alone did not lower PSA levels in men with low-volume prostate cancer.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    University of California, Davis, Sacramento, California 95616, USA.

    , , , ,

    Source

    Nutrition and cancer 62:8 2010 pg 1036-43

    MeSH

    Aged
    Aged, 80 and over
    Antineoplastic Agents, Phytogenic
    Biomarkers, Tumor
    Dietary Supplements
    Double-Blind Method
    Equol
    Genistein
    Humans
    Isoflavones
    Male
    Middle Aged
    Phytotherapy
    Plant Extracts
    Polysaccharides
    Prostate-Specific Antigen
    Prostatic Neoplasms
    Severity of Illness Index
    Soybeans
    Time Factors

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, N.I.H., Extramural
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    21058191

    Citation

    deVere White, Ralph W., et al. "Effects of a High Dose, Aglycone-rich Soy Extract On Prostate-specific Antigen and Serum Isoflavone Concentrations in Men With Localized Prostate Cancer." Nutrition and Cancer, vol. 62, no. 8, 2010, pp. 1036-43.
    deVere White RW, Tsodikov A, Stapp EC, et al. Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutr Cancer. 2010;62(8):1036-43.
    deVere White, R. W., Tsodikov, A., Stapp, E. C., Soares, S. E., Fujii, H., & Hackman, R. M. (2010). Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutrition and Cancer, 62(8), pp. 1036-43. doi:10.1080/01635581.2010.492085.
    deVere White RW, et al. Effects of a High Dose, Aglycone-rich Soy Extract On Prostate-specific Antigen and Serum Isoflavone Concentrations in Men With Localized Prostate Cancer. Nutr Cancer. 2010;62(8):1036-43. PubMed PMID: 21058191.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. AU - deVere White,Ralph W, AU - Tsodikov,Alexander, AU - Stapp,Eschelle C, AU - Soares,Stephanie E, AU - Fujii,Hajime, AU - Hackman,Robert M, PY - 2010/11/9/entrez PY - 2010/11/9/pubmed PY - 2011/3/9/medline SP - 1036 EP - 43 JF - Nutrition and cancer JO - Nutr Cancer VL - 62 IS - 8 N2 - The efficacy and safety of consuming high-dose isoflavone supplements for prostate cancer is not clear. A double-blind, placebo controlled, randomized trial was conducted in 53 men with prostate cancer enrolled in an active surveillance program. The treatment group consumed a supplement containing 450 mg genistein, 300 mg daidzein, and other isoflavones daily for 6 mo. Prostate-specific antigen (PSA) was measured in both groups at baseline, 3 mo, and 6 mo, and serum concentrations of genistein, daidzein, and equol were assessed at baseline and 6 mo in the treatment group. Following the completion of the 6-mo double-blind study, men were enrolled in a 6-mo open label trial with the same isoflavone-rich supplement, and PSA was measured at 3 and 6 mo. PSA concentrations did not change in either group after 6 mo or after 12 mo when the open-label study was included. The 6 mo serum concentrations of genistein and daidzein (39.85 and 45.59 μmol/l, respectively) were significantly greater than baseline values and substantially higher than levels previously reported in other studies. Equol levels did not change. Although high amounts of aglycone isoflavones may result in significantly elevated serum concentrations of genistein and daidzein, these dietary supplements alone did not lower PSA levels in men with low-volume prostate cancer. SN - 1532-7914 UR - https://www.unboundmedicine.com/medline/citation/21058191/Effects_of_a_high_dose_aglycone_rich_soy_extract_on_prostate_specific_antigen_and_serum_isoflavone_concentrations_in_men_with_localized_prostate_cancer_ L2 - http://www.tandfonline.com/doi/full/10.1080/01635581.2010.492085 DB - PRIME DP - Unbound Medicine ER -